A randomized Phase II study comparing SOX+B-mab with SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with KRAS wild type.

Trial Profile

A randomized Phase II study comparing SOX+B-mab with SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with KRAS wild type.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Bevacizumab; Cetuximab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 14 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top